Literature DB >> 20931248

Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.

Eduardo L G Moreira1, Daniel Rial, Aderbal S Aguiar, Cláudia P Figueiredo, Jarbas M Siqueira, Silvia DalBó, Heros Horst, Jade de Oliveira, Gianni Mancini, Tiago S dos Santos, Jardel G Villarinho, Francielle V Pinheiro, José Marino-Neto, Juliano Ferreira, Andreza F De Bem, Alexandra Latini, Moacir G Pizzolatti, Rosa M Ribeiro-do-Valle, Rui D S Prediger.   

Abstract

We have recently demonstrated that rodents treated intranasally with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) suffered impairments in olfactory, cognitive and motor functions associated with time-dependent disruption of dopaminergic neurotransmission in different brain structures conceivably analogous to those observed during different stages of Parkinson's disease (PD). On the other hand, the proanthocyanidin-rich fraction (PRF) obtained from the bark of Croton celtidifolius Baill (Euphorbiaceae), a tree frequently found in the Atlantic forest in south Brazil, has been described to have several neurobiological activities including antioxidant and anti-inflammatory properties, which may be of interest in the treatment of PD. The present data indicated that the pretreatment with PRF (10 mg/kg, i.p.) during five consecutive days was able to prevent mitochondrial complex-I inhibition in the striatum and olfactory bulb, as well as a decrease of the enzyme tyrosine hydroxylase expression in the olfactory bulb and substantia nigra of rats infused with a single intranasal administration of MPTP (1 mg/nostril). Moreover, pretreatment with PRF was found to attenuate the short-term social memory deficits, depressive-like behavior and reduction of locomotor activity observed at different periods after intranasal MPTP administration in rats. Altogether, the present findings provide strong evidence that PRF from C. celtidifolius may represent a promising therapeutic tool in PD, thus being able to prevent both motor and non-motor early symptoms of PD, together with its neuroprotective potential.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20931248     DOI: 10.1007/s00702-010-0464-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  80 in total

Review 1.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

2.  3-Hydroxyglutaric acid moderately impairs energy metabolism in brain of young rats.

Authors:  A Latini; M Rodriguez; R Borba Rosa; K Scussiato; G Leipnitz; D Reis de Assis; G da Costa Ferreira; C Funchal; M C Jacques-Silva; L Buzin; R Giugliani; A Cassina; R Radi; M Wajner
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 3.  Neuroprotective and neurorestorative strategies for Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Nat Neurosci       Date:  2002-11       Impact factor: 24.884

4.  Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.

Authors:  Marcelo Machado Ferro; Maria Ines Bellissimo; Janete Aparecida Anselmo-Franci; Miriam Elizabeth Mendes Angellucci; Newton Sabino Canteras; Claudio Da Cunha
Journal:  J Neurosci Methods       Date:  2005-06-06       Impact factor: 2.390

5.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

6.  Mechanisms underlying the vasorelaxant effect induced by proanthocyanidin-rich fraction from Croton celtidifolius in rat small resistance arteries.

Authors:  Silvia DalBó; Eduardo Gasnhar Moreira; Fernanda Costa Brandão; Heros Horst; Moacir Geraldo Pizzolatti; Gustavo Amadeu Micke; Rosa Maria Ribeiro-do-Valle
Journal:  J Pharmacol Sci       Date:  2008-02       Impact factor: 3.337

Review 7.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

Authors:  Anthony H V Schapira; C Warren Olanow
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

8.  Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.

Authors:  Rui D S Prediger; Daniel Rial; Rodrigo Medeiros; Cláudia P Figueiredo; Richard L Doty; Reinaldo N Takahashi
Journal:  Ann N Y Acad Sci       Date:  2009-07       Impact factor: 5.691

9.  Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons.

Authors:  Emily K Schroeder; Natalie A Kelsey; Jeanne Doyle; Elise Breed; Ron J Bouchard; F Alexandra Loucks; R Alex Harbison; Daniel A Linseman
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

10.  Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration.

Authors:  R L Doty; D A Deems; S Stellar
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

View more
  22 in total

Review 1.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

2.  The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors.

Authors:  Marissa Giovanna Schamne; Josiel Mileno Mack; Morgana Moretti; Filipe Carvalho Matheus; Roger Walz; Laurence Lanfumey; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2018-05-28       Impact factor: 3.911

3.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

4.  Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson׳s disease.

Authors:  Katherine E Strathearn; Gad G Yousef; Mary H Grace; Susan L Roy; Mitali A Tambe; Mario G Ferruzzi; Qing-Li Wu; James E Simon; Mary Ann Lila; Jean-Christophe Rochet
Journal:  Brain Res       Date:  2014-02-03       Impact factor: 3.252

5.  Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.

Authors:  Naiani F Marques; Adalberto A Castro; Gianni Mancini; Fernanda L Rocha; Adair R S Santos; Rui D Prediger; Andreza Fabro De Bem; Carla I Tasca
Journal:  Neurotox Res       Date:  2017-11-21       Impact factor: 3.911

Review 6.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

7.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

Review 8.  Selective MAO-B inhibitors: a lesson from natural products.

Authors:  Simone Carradori; Melissa D'Ascenzio; Paola Chimenti; Daniela Secci; Adriana Bolasco
Journal:  Mol Divers       Date:  2013-11-12       Impact factor: 2.943

9.  Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Aderbal S Aguiar; Fabrine S M Tristão; Majid Amar; Caroline Chevarin; Laurence Lanfumey; Raymond Mongeau; Olga Corti; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-04-16       Impact factor: 3.911

10.  Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)).

Authors:  Morgana Moretti; Vivian Binder Neis; Filipe Carvalho Matheus; Mauricio Peña Cunha; Priscila Batista Rosa; Camille Mertins Ribeiro; Ana Lúcia S Rodrigues; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2015-07-09       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.